Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Engineering mRNA Workflows for Disc Repair
2026-09-15
The emerging strategy of LNP-mRNA-engineered fibroblasts reframes mRNA synthesis as a translational design variable. This article connects inflammatory biology, transcript production, cell engineering, and preclinical decision-making for researchers developing localized regenerative therapies.
SpCas9 mRNA: Designing Transient CRISPR Editing
2026-09-15
SpCas9 mRNA enables transient CRISPR-Cas9 genome editing without introducing a DNA expression cassette. This guide connects mRNA chemistry, embryo delivery, repair biology, and assay design to help researchers plan more interpretable genome engineering experiments.
Protease Inhibitor Cocktail for Plant Assays
2026-09-14
Protect plant proteins from extraction through Western blotting, co-immunoprecipitation, pull-down, and kinase workflows with an EDTA-free, broad-spectrum formulation. This practical guide connects plant protein preservation with SHP2 mutation research while clearly separating validated product use from cross-domain experimental hypotheses.
Nitrocefin: Practical β-Lactamase Assay Workflows
2026-09-14
Nitrocefin converts β-lactamase activity into a rapid yellow-to-red signal for resistance profiling, enzyme characterization, and inhibitor screening. This guide connects practical assay setup with a peptide-discovery workflow reported for TEM-1 β-lactamase, including controls, optimization strategies, and troubleshooting.
Anti-ROR1 Antibody (Zilovertamab) Guide
2026-09-13
Anti-ROR1 Antibody (Zilovertamab) is a humanized IgG1 reagent designed to bind ROR1 and inhibit Wnt5a-induced ROR1 signaling. The F1460 product supports ELISA, FACS, kinetic, functional, and animal-model workflows, but its product-level binding data do not establish clinical efficacy or activity in deoxynivalenol-induced liver injury.
Concanavalin A Targets Conserved Coronavirus Glycans
2026-09-12
This study identifies phylogenetically conserved N-linked glycans near the coronavirus spike S2′ cleavage site as a broad-spectrum antiviral vulnerability. Using fusion, pseudovirus, authentic infection, biochemical, and animal models, the authors show that concanavalin A blocks spike activation and reduces hCoV-NL63 disease-related outcomes in mice.
Targeting Fructose Metabolism in Cancer Therapy
2026-09-12
This 2025 Cancer Letters review integrates fructose transport, the polyol pathway, tumor bioenergetics, mTORC1 signaling, and immune regulation into a unified framework for cancer therapy. Its main practical implication is that fructose metabolism may offer both biomarker opportunities and combination-treatment targets, although the evidence remains primarily mechanistic and preclinical.
Torin2: Potent mTOR Inhibitor for Cancer Research
2026-09-11
Torin2 is a highly potent, selective mTOR inhibitor with a reported EC50 of 0.25 nM in the product potency assay. Its cellular, tissue-exposure, and medullary thyroid carcinoma data support pathway-dissection studies, while recent RNA Pol II research provides a mechanistic apoptosis framework that should not be directly attributed to Torin2 without validation.
Recombinant Mouse IFN-γ in MASH-HCC Assays
2026-09-11
Use Recombinant Mouse IFN-γ as a controlled challenge to distinguish defective tumor antigen presentation from downstream immune-cell failure in MASH-HCC models. This workflow combines cytokine rescue, bile-acid stress, NLRC5/MHC-I readouts, and functional validation for more interpretable immunotherapy studies.
Difloxacin HCl: Assay Workflows and Use Cases
2026-09-10
Difloxacin HCl supports two distinct research paths: bacterial DNA replication inhibition for antimicrobial susceptibility testing and exploratory multidrug resistance reversal through MRP substrate sensitization. This practical guide covers formulation, controls, workflow design, checkpoint-biology context, and troubleshooting without treating research results as clinical recommendations.
Thymoquinone in Doxorubicin Cardiotoxicity Models
2026-09-10
Thymoquinone offers a practical probe for connecting cardiac function, oxidative stress, mitochondrial injury, and ferroptosis in doxorubicin models. This workflow translates recent mouse findings into formulation controls, orthogonal assays, and troubleshooting steps for more reproducible cardioprotection studies.
From Bile-Acid Subtypes to qPCR Biomarkers
2026-09-09
A translational analysis of how bile acid metabolism signatures in colorectal cancer can be converted into reproducible qPCR biomarkers using robust reverse transcription, genomic DNA contamination control, and disciplined validation.
Peptidisc-Assisted Nanobody Clustering: Study Insights
2026-09-09
This bioRxiv preprint describes a peptidisc-assisted strategy for clustering nanobodies through hydrophobic transmembrane segments, producing multimeric assemblies called polybodies. The reported avidity gains, bispecific assemblies, and autofluorescent constructs suggest a flexible route to multifunctional binders, while the preprint status and limited quantitative detail require careful validation.
SB 225002 and the CXCR2–IL-8 Decision Point
2026-09-08
The IL-8 axis is not a single pathway: receptor usage can separate tumor-cell proliferation from neutrophil trafficking. This thought-leadership analysis positions SB 225002 as a selective CXCR2 tool for testing that distinction in inflammation, cancer, and infection-associated microenvironment models.
Phosphatase Inhibitor Cocktail 1 Workflow
2026-09-07
Protect labile phosphorylation states from cell harvest through Western blotting, co-immunoprecipitation, and phosphoproteomic analysis. This workflow combines a practical 1X starting condition with tissue-panel guidance inspired by UPF3A expression research, while highlighting controls and troubleshooting limits.